Claims
- 1. A substantially pure peptide of the formula ##STR15## where x is independently selected from the group consisting of:
- KILAVERYLKDQQLLGIWG (586-604)
- KKILAVERYLKDQQLLGIWG (585-604),
- amino acid sequences corresponding thereto, which amino acid sequences are derived from homologous regions of other HIV-1 isolates and amino acid sequences differing from the above as a result of conservative amino acid substitutions, such peptides being characterized by at least one of a lysine at position 586 or a lysine at both position 585 and 586;
- y, if present, is independently selected from the group consisting of:
- --T
- --TT
- --TTA
- --TTAV
- --TTAVP
- --TTAVPW
- --TTAVPWN
- --TTAVPWNA
- --TTAVPWNAS
- --TTAVPWNASW
- --TTAVPWNASWS
- --TTAVPWNASWSN
- --TTAVPWNASWSNK
- --TTAVPWNASWSNKS
- --TTAVPWNASWSNKSL
- --TTAVPWNASWSNKSLE
- --TTAVPWNASWSNKSLEQ
- --TTAVPWNASWSNKSLEQI,
- amino acid sequences corresponding thereto which amino acid sequences are derived from homologous regions of other HIV-1 isolates and amino acid sequences differing from the above as a result of conservative amino acid substitutions;
- a is an amino terminus or a substituent effective as a coupling agent and/or to make the peptide more useful as an immunodiagnostic reagent without changing its antigenic properties; and
- b is a carboxy terminus or a substituent effective as a coupling agent and/or to make the peptide more useful as an immunodiagnostic reagent without changing its antigenic properties.
- 2. A substantially pure peptide of the formula: ##STR16## wherein x.sup.1 is independently selected from the group consisting of:
- KVTAIEKYLQDQARLNSWG (578-596)
- KKVTAIEKYLQDQARLNSWG (577-596),
- amino acid sequences corresponding thereto which amino acid sequences are derived from homologous regions of other HIV-2 isolates and amino acid sequences differing from the above as a result of conservative amino acid substitutions, such amino acid sequences being characterized by at least one of a lysine at position 578 or a lysine at both positions 577 and 578;
- y.sup.1, if present, is independently selected from the group consisting of:
- --H
- --HT
- --HTT
- --HTTV
- --HTTVP
- --HTTVPW
- --HTTVPWV
- --HTTVPWVN
- --HTTVPWVND
- --HTTVPWVNDS,
- amino acid sequences corresponding thereto which amino acid sequences are derived from homologous regions of other HIV-2 isolates and amino acid sequences differing from the above as a result of conservative amino acid substitutions;
- a is an amino terminus or a substituent effective as a coupling agent and/or to make the peptide more useful as an immunodiagnostic reagent without changing its antigenic properties; and
- b is a carboxy terminus or a substituent effective as a coupling agent and/or to make the peptide more useful as an immunodiagnostic reagent without changing its antigenic properties.
- 3. The peptide according to claim 1, wherein x is KILAVERYLKDQQLLGIWG and y is TTAVPWNAS.
- 4. The peptide according to claim 1, wherein x is KKILAVERYLKDQQLLGIWG and y is TTAVPWNAS.
- 5. The peptide according to claim 2, wherein x.sup.1 is KVTAIEKYLQDQARLNSWG and y.sup.1 is HTTVPWVNDS.
- 6. The peptide according to claim 2, wherein x.sup.1 is KKVTAIEKYLQDQARLNSWG and y.sup.1 is HTTVPWVNDS.
- 7. A mixture comprising two or more peptides selected from the group consisting of the peptides of any one of claims 1 and 2.
- 8. The mixture according to claim 7 comprising at least the following peptide: ##STR17## amino acid sequences corresponding thereto, which amino acid sequences are derived from homologous regions of other HIV-1 isolates and amino acid sequences differing from the above as a result of conservative amino acid substitutions, such amino acid sequences being characterized by a lysine at position 586.
- 9. The mixture according to claim 7 comprising at least the following peptide: ##STR18## amino acid sequences corresponding thereto, which amino acid sequences are derived from homologous regions of other HIV-2 isolates and amino acid sequences differing from the above as a result of conservative amino acid substitutions, such amino acid sequences being characterized by a lysine at position 578.
Parent Case Info
This is a continuation-in-part of U.S. patent application Ser. Nos. 07/148,821 filed on Jan. 27, 1988, 07/185,518 filed Apr. 22, 1988, and 07/281,205 filed Dec. 8, 1988.
US Referenced Citations (6)
Foreign Referenced Citations (6)
Number |
Date |
Country |
0219106 |
Apr 1987 |
EPX |
0231914 |
Aug 1987 |
EPX |
0233045 |
Aug 1987 |
EPX |
0247557 |
Dec 1987 |
EPX |
8606414 |
Nov 1986 |
WOX |
8903844 |
May 1989 |
WOX |
Non-Patent Literature Citations (4)
Entry |
Bolognesi, D. TIBTECH, vol. 8: 40-45, 1990. |
Gnann, J. et al., J. of Virology, 61(8): 2639-2641, Aug. 1987. |
Gnann, J. et al., J. of Infectious Disease; 156(2): 261-267, Aug. 1987. |
Gnann, J. et al., Science, 237: 1346-1349, Sep. 1987. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
148821 |
Jan 1988 |
|